Estimating the Cost-Effectiveness of Fluticasone Propionate for Treating Chronic Obstructive Pulmonary Disease in the Presence of Missing Data
Authors:
- Andrew H. BriggsABAndrew H. Briggs
- Greta Lozano-OrtegaGLGreta Lozano-Ortega
- Sally SpencerSSSally Spencer
- Geraldine BaleGBGeraldine Bale
- Michael D. SpencerMSMichael D. Spencer
- P. Sherwood BurgePBP. Sherwood Burge
- 1 July 2006
- journal article
- Published by Elsevier in Value in Health
- Vol. 9 (4) , 227-235
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Estimating mean QALYs in trial‐based cost‐effectiveness analysis: the importance of controlling for baseline utilityHealth Economics, 2004
- National Institute for Clinical Excellence and its value judgmentsBMJ, 2004
- Chronic obstructive pulmonary disease * 7: Management of COPDThorax, 2003
- Methods to Analyse Cost Data of Patients Who Withdraw in a Clinical Trial SettingPharmacoEconomics, 2003
- Modern treatment of chronic obstructive pulmonary diseaseEuropean Respiratory Journal, 2001
- Quality of life and hospital re-admission in patients with chronic obstructive pulmonary diseaseThorax, 1997
- Confidence intervals for cost-effectiveness ratios: An application of Fieller's theoremHealth Economics, 1996
- Multiple Imputation after 18+ YearsJournal of the American Statistical Association, 1996
- Costs, effects and C/E‐ratios alongside a clinical trialHealth Economics, 1994
- The CE PlaneMedical Decision Making, 1990